Daily Respiratory Research Analysis
Three impactful respiratory studies emerged: mechanistic immunology showing that common cold coronavirus imprinting can prime broadly neutralizing S2 antibodies and inform pan‑coronavirus vaccine design; a COPD microbiome study revealing disease‑linked disruptions in bacteriophage ecology; and a large cohort comparing post‑acute sequelae after COVID‑19 versus influenza, highlighting severity‑driven risk and mitigation by antivirals and vaccination.
Summary
Three impactful respiratory studies emerged: mechanistic immunology showing that common cold coronavirus imprinting can prime broadly neutralizing S2 antibodies and inform pan‑coronavirus vaccine design; a COPD microbiome study revealing disease‑linked disruptions in bacteriophage ecology; and a large cohort comparing post‑acute sequelae after COVID‑19 versus influenza, highlighting severity‑driven risk and mitigation by antivirals and vaccination.
Research Themes
- Immune imprinting and pan-coronavirus vaccine strategies
- Airway virome and bacteriophage ecology in COPD
- Comparative post-acute sequelae after respiratory viral infections
Selected Articles
1. Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.
This mechanistic study shows that immune imprinting by common cold embecovirus OC43 back-boosts antibody-secreting cells to generate broadly cross-reactive, neutralizing, and protective antibodies to conserved S2 epitopes. It proposes a vaccine strategy using OC43 priming followed by SARS-CoV-2 boosting to enhance pan-coronavirus protection.
Impact: It uncovers a previously underappreciated pathway to elicit neutralizing S2 responses and offers a concrete, testable blueprint for pan-coronavirus vaccine design.
Clinical Implications: Although preclinical, the findings support evaluating controlled OC43 priming and SARS-CoV-2 boosting to broaden protection, informing next-generation vaccine trials aiming at cross-lineage and pan-betacoronavirus coverage.
Key Findings
- Convalescent S2-targeting antibodies were largely non-neutralizing and restricted to closely related sarbecoviruses.
- First-exposure severe COVID-19 patients mounted OC43-imprinted, back-boosted ASC responses yielding broadly cross-reactive, neutralizing, and protective antibodies across up to five betacoronavirus subgenera.
- Two S2 antigenic sites were defined: a stem-helix–competitive site and a distinct apex epitope; controlled OC43 priming followed by SARS-CoV-2 boosting is proposed to improve S2 vaccine breadth.
Methodological Strengths
- Human cohorts spanning differing exposure histories with detailed B-cell/ASC profiling and epitope mapping
- Demonstration of neutralization and protection with site-specific competition analyses
Limitations
- Observational human immunology with limited sample sizes and potential selection bias
- Vaccine priming/boosting strategy not yet validated in clinical trials
Future Directions: Test OC43 priming/SARS-CoV-2 boosting regimens in controlled trials; structural vaccinology to optimize S2 immunogen presentation at the stem-helix and apex epitopes; assess durability and breadth across variants.
The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses.
2. Bacteriophage diversity declines with COPD severity in the respiratory microbiome.
Re-analysis of sputum metagenomes revealed that COPD severity is linked to declining respiratory virome diversity and disrupted phage–bacteria coupling, particularly in frequent exacerbators. Select phages (e.g., Porphyromonas phages) were disproportionately depleted, and virulence factor–encoding Haemophilus phages associated with explosive bacterial overgrowth.
Impact: Introduces bacteriophage ecology as a key, overlooked component of COPD pathobiology and identifies actionable targets/biomarkers for microbiome‑modulating interventions.
Clinical Implications: Phage signatures could stratify COPD phenotypes (e.g., frequent exacerbators) and inform future phage/probiotic therapies or surveillance for virulence factor–encoding phages to mitigate dysbiosis.
Key Findings
- Identified 1,308 viral OTUs with stepwise decline in viral diversity paralleling COPD severity.
- Frequent exacerbators showed decoupled viral–bacterial diversity, indicating disrupted ecological dynamics.
- Porphyromonas-infecting phages were 40-fold less abundant despite only 4-fold lower bacterial abundance; neuA-carrying Haemophilus phages occurred in 7.4% and associated with 82-fold higher Haemophilus abundance.
Methodological Strengths
- Comprehensive virome profiling across 135 sputum metagenomes with COPD severity stratification and controls
- Integrated analysis of viral–bacterial diversity correlations and detection of virulence factor–encoding phages
Limitations
- Sputum sampling may not fully reflect lower airway ecology; cross-sectional design limits causal inference
- Potential confounding by medications, smoking, or comorbidities not fully controlled
Future Directions: Longitudinal, compartment-specific sampling (bronchoscopy) to test causality; interventional studies targeting phage communities; development of phage-based diagnostics and therapeutics in COPD.
Chronic obstructive pulmonary disease (COPD) severity correlates with airway microbial dysbiosis, yet bacteriophage roles remain unexplored. We characterized the lung DNA virome by re-analyzing 135 sputum metagenomes from 99 COPD patients and 36 healthy controls. We identified 1,308 viral operational taxonomic units, revealing progressively lower viral diversity correlating with disease severity. While viral and bacterial diversity typically showed strong positive correlations, patients with frequent exacerbations uniquely exhibited decoupled viral-bacterial relationships, indicating disrupted ecological dynamics. Comparing all COPD patients to controls, phages infecting anaerobic oral bacteria showed disproportionately lower abundance-Porphyromonas phages were 40-fold less abundant, despite only 4-fold lower bacterial abundance-while pathogen-associated phages showed no significant differences. We detected virulence factor-encoding phages, including two neuA-carrying Haemophilus phages in 7.4% of Haemophilus-colonized patients, associated with 82-fold higher bacterial abundance. These findings establish altered bacteriophage ecology as an unrecognized feature of COPD pathobiology, with differential phage-bacteria relationships that reshape lung microbial ecosystems, offering new perspectives for microbiome-targeted interventions.
3. Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults.
In a 93,528-case retrospective cohort, post-acute healthcare use after non-severe SARS-CoV-2 infection was similar to influenza, whereas severe PAS requiring hospitalization was higher after COVID-19, particularly among those hospitalized during the acute phase. Antiviral treatment and up-to-date vaccination attenuated severe PAS risk.
Impact: Clarifies that much of post-acute morbidity is shared across respiratory viruses while pinpointing severe PAS risk to initially severe COVID-19, informing prioritization for follow-up and prevention.
Clinical Implications: Prioritize longitudinal monitoring for patients hospitalized with acute COVID-19; optimize early antiviral use and vaccination to mitigate severe PAS; recognize that influenza’s long-term burden may be underappreciated in clinical pathways.
Key Findings
- PAS-related healthcare utilization was only modestly higher after COVID-19 vs influenza within 31–90 days (aHR 1.04) and attenuated by 91–180 days (aHR 1.01).
- Severe PAS requiring hospitalization was higher after COVID-19 at both 31–90 days (aHR 1.31) and 91–180 days (aHR 1.24), concentrated among those hospitalized during the acute phase.
- Antiviral therapy and up-to-date vaccination mitigated severe PAS risk; findings are based on healthcare utilization and do not include patient-reported outcomes.
Methodological Strengths
- Very large integrated healthcare cohort with robust adjustment and weighting across care settings
- Stratification by acute severity, antiviral treatment, and vaccination status
Limitations
- Outcomes limited to healthcare utilization; lacks patient-reported symptoms and quality-of-life measures
- Residual confounding inherent to retrospective observational design
Future Directions: Prospective cohorts including patient-reported outcomes, functional measures, and biomarkers; pragmatic trials to test whether early antivirals/vaccination reduce severe PAS in high-risk patients.
BACKGROUND: Post-acute sequelae (PAS) of SARS-CoV-2 infection are well documented. However, it remains unclear whether such long-term health effects are unique to COVID-19, or also occur following other viral respiratory infections. METHODS AND FINDINGS: We undertook a retrospective cohort study of 74,738 COVID-19 cases and 18,790 influenza cases within the Kaiser Permanente Southern California healthcare system diagnosed between 1 September, 2022 and 31 December, 2023. Cases received care for index infections across a spectrum of clinical settings, spanning virtual (n = 35,835; 38.3%), ambulatory (n = 26,579; 28.4%), emergency department (n = 23,388; 25.0%) and inpatient (n = 7,726; 8.3%) facilities. We compared 180-day risk of PAS-related healthcare utilization among COVID-19 cases and influenza via adjusted hazard ratios (aHRs) weighted to account for cases' index infection type and follow-up retention. Adjustment models addressed patients' demographic characteristics, comorbidity profiles, prior healthcare utilization patterns, and index episode severity. Risk of PAS diagnoses in any clinical setting was only modestly higher among COVID-19 cases in comparison to influenza cases within 31-90 days after cases' initial illness (aHR = 1.04 [95% confidence interval: 0.99, 1.09]; risk difference = 0.6 [-0.1, 1.2] cases per 100 person-months). This difference was attenuated by 91-180 days (aHR = 1.01 [0.97, 1.06]; risk difference = 0.4 [-0.1, 0.9] cases per 100 person-months). However, COVID-19 cases faced higher risk of severe PAS conditions requiring hospitalization (aHR = 1.31 [1.07, 1.59] and 1.24 [1.03, 1.49] within 31-90 and 91-180 days, respectively). This excess risk of severe PAS was concentrated among COVID-19 cases hospitalized during acute-phase illness, and was attenuated among cases who received antiviral treatment, who had up-to-date vaccination status prior to infection, or who did not require inpatient admission for acute-phase illness. As a limitation, analyses included only PAS resulting in healthcare utilization; patient-reported symptoms and quality-of-life measures were not captured. CONCLUSIONS: In this large, real-world cohort, individuals with non-severe acute respiratory illness caused by SARS-CoV-2 experienced only modestly greater risk of PAS in comparison to those whose illness was caused by influenza. However, COVID-19 cases hospitalized for their initial illness experienced greater risk of severe PAS necessitating inpatient care, and this difference persisted through 180 days of follow-up. Our findings challenge assumptions about the uniqueness of post-acute COVID-19 morbidity and suggest the long-term burden of influenza may be underrecognized.